Clinical trial
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+…
NCT00499681 · Vanderbilt-Ingram Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00499681 |
|---|---|
| Title | PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE |
| Official title | A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | lapatinib ditosylate, letrozole, placebo |
| Enrollment | 6 |
| Start date | Jul 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Dec 1, 2010 |
| First posted | Jul 11, 2007 |
| Last update posted | Aug 10, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: